Case series / case reportcited by the Tayebat archiveabstract only checked A-CHM-15 standard review

Leukaemia caused by earlier cancer treatment has a poor outlook

Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.

Overview

Smith SM et al.. Blood 2003 · PMID 12623843 · DOI 10.1182/blood-2002-11-3343

In 306 patients, median survival after diagnosis was 8 months.

Does the study support the specific claim? Yes · Methodological quality: low

Study explained simply

What did the researchers want to find out?: Describe t-MDS/AML.
How was the study done?: Case series.
How many people, animals or samples were studied?: 306.
What was actually found?: Typical chromosome changes; poor survival.
How large was the observed effect?: Median survival 8 months.
What do the results mean in everyday life?: Rare but serious complication.
What are the study's limitations?: No incidence data.
What does it say about Elawady's specific claim?: Supports existence.
Do the results apply to Germany and Europe?: Moderate.
What can explicitly not be concluded from this study?: How often it happens.

Authors: Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, Vardiman JW, Rowley JD, Larson RA
Journal: Blood
Year: 2003
Identifier: PMID 12623843 DOI 10.1182/blood-2002-11-3343
Verification: verified (PMID in archive was wrong, corrected) – PubMed E-utilities efetch, 2026-10-25
Retracted: no
Corrections: none
Extent checked: abstract only
Conflicts of interest and funding: not stated in abstract | Grants: NCI NIH HHS

Clinical-cytogenetic features of therapy-related MDS/AML.

Study design: Case series / case report – Single-institution consecutive case series
Population: Patients referred with t-MDS/t-AML since 1972
Country: USA (University of Chicago)
Period: 1972 onward
Sample size: 306
Inclusion and exclusion criteria: Consecutive referred t-MDS/t-AML

Results: Alkylating agents 78%, topoisomerase-2 inhibitors 39%; 92% clonal abnormalities (chromosomes 5/7 in 76% of abnormal karyotypes). Balanced rearrangements: shorter latency (28 vs 67 months). Median survival after t-MDS/t-AML 8 months; 5-year survival <10%.
Absolute risks: not applicable (no denominator of exposed patients)
Authors' conclusion: Confirms associations between clinical, morphological and cytogenetic findings in t-MDS/t-AML.

Describes severity once t-MDS/AML occurs; says nothing about how often it occurs.

Supports existence and severity of therapy-related leukaemia.

A-CHM-07 for absolute magnitude of second cancers.

Moderate.

Valid as illustration of a serious but uncommon complication.

Multidimensional assessment
Multidimensional assessment
Authenticity of the source	verified (PMID in archive was wrong, corrected)
Methodological quality	low
Risk of bias	not assessable
Precision of results	not applicable
Directness	direct
Reproducibility	unknown
Consistency with the overall evidence	unknown
Regional transferability	moderate
Adequacy of the interpretation (by the archive)	essentially correct but incomplete

Incidence under modern regimens.

Note: according to the archive, the studies were compiled by the archive operators. Whether Dr. Elawady himself cited this study is not established.

What the archive says about the study: Cited for therapy-related myeloid leukaemia as a secondary cancer.
A. What was actually studied?: Features of t-MDS/AML.
B. What did the authors find?: Poor prognosis; typical cytogenetics.
C. What conclusions do the authors themselves draw?: Confirms clinical-cytogenetic associations.
D. What does the archive derive from it?: Secondary leukaemia years after cure.
E. Is this derivation scientifically justified?: Yes for existence and severity; frequency cannot be derived from a case series.
Adequacy of the interpretation (by the archive): essentially correct but incomplete